Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HEXVIX VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.

Next Previous
Trial Profile

HEXVIX VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hexyl aminolevulinate (Primary) ; Mitomycin; Mitomycin
  • Indications Bladder cancer
  • Focus Diagnostic use
  • Acronyms HELENA

Most Recent Events

  • 05 Feb 2021 This trial has been completed in Germany, according to European Clinical Trials Database record. (Global end date:2020-10-30)
  • 10 Nov 2012 Planned end date changed from 8 Sep 2011 to 8 Jan 2015 as reported by European Clinical Trials Database.
  • 15 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top